Introduction
============

Colorectal cancer (CRC) is one of the most common malignant tumors and is the third highest cancer for incidence and has the second highest mortality (9.2%) of different types of cancer worldwide ([@b1-ol-0-0-9924]). The principal treatments used for CRC are surgery, radiation therapy, chemotherapy and molecular targeted therapy. As a novel treatment type, molecular targeted therapy has been used in a variety of tumors including CRC ([@b2-ol-0-0-9924],[@b3-ol-0-0-9924]). The therapeutic strategy to target the selected epidermal growth factor receptor has been developed in clinical trials ([@b4-ol-0-0-9924]). However, it possesses drug resistance in the treatment of patients with CRC harboring the V600E mutation of B-Raf proto-oncogene serine/threonine kinase (BRAF^V600E^) mutation ([@b5-ol-0-0-9924],[@b6-ol-0-0-9924]). BRAF is an important oncogene and mutant BRAF has been implicated in the pathogenesis of several types of cancer. The 1796T\>A mutation results in an amino acid substitution at position 600 in BRAF, from valine to glutamic acid. This mutation occurs within the activation segment of the kinase domain and leads to the continuous activation of the MAPK/ERK signaling pathway ([@b7-ol-0-0-9924],[@b8-ol-0-0-9924]). Although oral BRAF inhibitors have remarkable clinical activity in metastatic melanomas with BRAF^V600E^, resistance to therapy invariably develops in patients with CRC with the same BRAF mutation ([@b9-ol-0-0-9924],[@b10-ol-0-0-9924]). Therefore, there is an urgent requirement to develop a novel and effective treatment for these patients.

Our previous study identified a novel gene monopolar spindle protein kinase 1 (Mps1), which is a downstream target of BRAF^V600E^, and continuously activated BRAF^V600E^ signaling may be a potential mechanism for the deregulation of Mps1 stability and kinase activity in human malignancies ([@b11-ol-0-0-9924],[@b12-ol-0-0-9924]). Persistent phosphorylation of Mps1 through BRAF^V600E^ signaling is a key event in disrupting the control of centrosome duplication and chromosome stability that may contribute to tumorigenesis ([@b13-ol-0-0-9924],[@b14-ol-0-0-9924]). Notably, phospho (p)-Ser^281^ Mps1 staining was demonstrated to be positively associated with p-mitogen-activated protein kinase (MAPK) \[extracellular-signal-regulated kinase ERK)1/2\] in human melanoma tissues ([@b13-ol-0-0-9924]). However, to the best of our knowledge, no previous study has investigated whether a correlation exists between BRAF and Mps1 in CRC.

In the present study, the incidence of BRAF^V600E^ was determined in CRC tissues, and the correlation of Mps1 and BRAF^V600E^ and p-ERK in Chinese patients with CRC was determined. The results raise the possibility that targeting the oncogenic BRAF and Mps1, particularly when used in combination, may potentially provide effective therapeutic opportunities for the treatment of CRC.

Materials and methods
=====================

### Patients and samples

The present study was approved by the Ethics Committee of Shanxi Medical University (Taiyuan, China), and patients provided written informed consent for their inclusion. A total of 288 (156 male and 132 female) paraffin-embedded tissue sections containing the carcinoma and its adjacent non-neoplastic colorectal tissue were obtained from The First Hospital of Shanxi Medical University and TaiYuan Municipal No. 2 People\'s Hospital collected between January 2009 and June 2015. Among them, there were 284 adenocarcinoma, 1 glandular squamous cell carcinoma, 1 signet-ring cell carcinoma and 2 neuroendocrine carcinoma tissues. The age of patients at the time of diagnosis with CRC ranged between 25 and 92 years, and the median age was 64 years. On the basis of Tumor-Node-Metastasis classification, there were 169 patients at stage I and II, 119 patients at stage IIIb and IV ([@b15-ol-0-0-9924]) 110 cases with lymph metastasis, and 178 cases without lymph node (LN) metastasis ([Table I](#tI-ol-0-0-9924){ref-type="table"}). All patients were diagnosed with CRC, with no previous history of other malignant tumor types, and had not received other treatments prior to surgery. In 183 cases \[168 cases with wild-type BRAF (BRAF^WT^) and 15 cases with BRAF^V600E^\], no cases of squamous cell carcinoma were identified. The complete clinical data and follow-up data were included in the survival analysis.

### DNA extraction

Surgically removed tissue was fixed in 10% buffered formalin for 24 h at room temperature and embedded in paraffin. Hematoxylin and eosin-stained tumor tissues (stained for 5 min and 30 sec at room temperature, respectively) were independently reviewed by two pathologists. DNA was extracted using the FFPE DNA kit (Omega Bio-Tek, Inc., Norcross, GA, USA), according to the manufacturer\'s protocol. The DNA concentration was determined using a NanoDrop 2000 instrument and the 260/280 nm ratio was calculated to evaluate the quality of DNA. The sample concentration was adjusted to 200--300 ng/µl, and DNA was stored at −80°C.

### Polymerase chain reaction (PCR)

Using the DNA template above, and a 252-bp fragment of BRAF exon 15 was obtained using PCR. The primers of BRAF were 5′-CTTGCCACAGGTCTCCCC-3′ (forward) and 5′-TCTAGTAACTCAGCAGCATCTCAGG-3′ (reverse). The PCR was carried out in 10 µl PCR buffer, 4 µl dNTP, 2 µl DNA, 1.5 µl forward primer, 1.5 µl reverse primer, 1 µl DNA polymerase (PrimeSTAR GXL DNA Polymerase TAKARA Japan) and double-distilled water for a total reaction volume of 50 µl. The amplification procedure was pre-denaturation for 3 min at 98°C, followed by 30 cycles of 30 sec at 98°C, 30 sec at 58°C and 30 sec at 72°C. The PCR product was examined by 2% agarose electrophoresis and stained by ethidium bromide, then detected under UV. Sanger sequencing was performed by Beijing Liuhe Huada Gene Technology Company (Beijing, China).

### Immunohistochemistry (IHC)

According to the sequencing results, 15 cases harboring BRAF^V600E^ and the same number of patients harboring BRAF^WT^ were randomly selected for IHC, with rabbit anti-human Mps1 antibody (cat. no. ab135819; Abcam, Cambridge, UK) and rabbit anti-human p-ERK antibody (cat. no. 4376; Cell Signaling Technology, Inc., Danvers, MA, USA) as primary antibodies, and horseradish peroxide (HRP)-labeled goat anti-rabbit immunoglobulin G (IgG; cat. no. A20120A0704; BioTNT, Shanghai, China) as a secondary antibody. A known positive tissue section served as a positive control. A negative control was established using PBS instead of the primary antibody.

The IHC analysis was performed as follows: 4 micron thick sections were moved to anhydrous ethanol for 2 min at room temperature, then placed in 95% ethanol liquid cylinder for 2 min, then moved to 85% ethanol liquid cylinder for 2 min, and finally placed in 75% ethanol liquid cylinder for 2 min, and then incubated in 3% hydrogen peroxide to block endogenous peroxidase for 15 min at room temperature, followed by washing with PBS three times and soaking in distilled water for 5 min. Antigen retrieval was performed with citrate liquid in a microwave at 92--98°C for 15 min. Sections were blocked with 10% goat serum (1201A Shanghai Biyun day Biotechnology Co., Ltd China) at 37°C for 30 min and rabbit anti-human Mps1 monoclonal antibody (1:100) or anti-p-ERK antibody (1:400) was added, and incubated at 4°C overnight. The slides were then washed with PBS three times and incubated with HRP-labeled goat anti-rabbit IgG at 37°C for 20 min, followed by washing with PBS three times and using 3,3′-diaminobenzidine as a chromogen. Sections were counterstained with hematoxylin for 1 min at room temperature, dehydrated in graded alcohol and sealed with resin sealing agent.

Fully automatic digital pathological scanning apparatus (Leica Microsystems, Inc., Buffalo Grove, IL, USA) were used to obtain high-resolution digital images. A total of five high-power fields of vision (×400 magnification) were randomly selected and analyzed using Image Scope software (12.0; Leica Microsystems, Inc.). The average value of the positive rate of five randomly selected fields of view was obtained using standardized cell nuclear analysis parameters. Nuclear p-ERK expression was classified as negative for 0--35 and positive for \>35. Mps1 expression in the cytoplasm was classified as negative for 0--70 and positive for \>70.

### Statistical analysis

Continuous variables are presented as the mean (SD), and categorical variables are presented as count values (percentages). The p-ERK and Mps1 positive expression levels were divided into four groups based on inter-quartile range respectively, which were 35--45.71, 45.71--51.14 51.14--65.54, and ≥65.54 for p-ERK, as well as 70--88.73, 88.73--117.33, 117.33--157.12 and ≥157.12 for Mps1. The differences were analyzed by χ^2^ test. χ^2^ test or Fisher\'s exact test was also used to assess the association between BRAF mutation status and clinical parameters. Univariate and multivariate survival analyses were performed using a Cox proportional hazards regression model. The contingency coefficient was used to evaluate the correlation between p-ERK and Mps1 expression. A sensitivity analysis was conducted using Spearman\'s rank analysis was performed to determine the correlation between p-ERK and Mps1. Kaplan-Meier survival analysis and the log-rank test were used to analyze the association between BRAF^V600E^ and prognosis. Data were analyzed using SPSS software (version 20.0; IBM Corp., Armonk, NY, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### BRAF^V600E^ mutation and its association with clinical parameters in CRC

Sanger DNA sequencing was used to detect the 1796T\>A (V600E) mutation, which was the most frequently observed mutation site in BRAF ([Fig. 1A and B](#f1-ol-0-0-9924){ref-type="fig"}). In 288 cases of colorectal cancer, 15 cases of BRAF mutation were identified. The rate of BRAF^V600E^ was 5.2% in CRC. A statistical analysis of BRAF mutations and clinical parameters revealed that BRAF^V600E^ was further associated with the age, infiltrating depth, pathological pattern of CRC, were more prevalent in older patients (\>60 years), infiltrating depth\>T3 stage patients and the mucinous tumors (χ^2^ test or Fisher\'s exact test P\<0.05; [Table II](#tII-ol-0-0-9924){ref-type="table"}). However, no association of the BRAF mutation with location, clinical stage, LN metastasis, differentiation and sex were identified (χ^2^ test or Fisher\'s exact test P\>0.05; [Table II](#tII-ol-0-0-9924){ref-type="table"}). Despite previous studies attempting to identify specific risk factors, no dietary and lifestyle factors have been clearly associated with the development of BRAF mutated CRC ([@b16-ol-0-0-9924]--[@b18-ol-0-0-9924]). The results of the present study suggest that the BRAF mutation was not associated with smoking, alcohol intake (χ^2^ test or Fisher\'s exact test P\>0.05; [Table II](#tII-ol-0-0-9924){ref-type="table"}).

### BRAF^V600E^ mutation is associated with a poor prognosis of patients with CRC

Kaplan-Meier survival analysis indicated that the survival rate was significantly lower in patients with BRAF^V600E^ mutation compared with those with BRAF^WT^ ([Fig. 1C](#f1-ol-0-0-9924){ref-type="fig"}). The median survival time of patients with BRAF^V600E^ and BRAF^WT^ were 300 and 429.5 days respectively.

Cox regression analysis was used to assess the impact of BRAF mutations and clinical parameters on OS. Notably, the results revealed that the association of BRAF mutations with OS was statistically significant (Cox regression multivariate analysis HR=0.32, P=0.051; [Fig. 2A](#f2-ol-0-0-9924){ref-type="fig"}; Cox regression univariate analyses, HR=0.36, P=0.03, [Fig. 2B](#f2-ol-0-0-9924){ref-type="fig"}). Although the P-value of BRAF^V600E^ in the multivariate analysis was 0.051These results suggested that BRAF^V600E^ may serve an important function in specific pathological CRC, and may function as an independent prognostic factor and a novel oncological therapeutic strategy.

### IHC and evaluation of p-ERK and Mps1 in CRC

According to the sequencing results, 15 cases harboring BRAF^V600E^ and the same number of patients harboring BRAF^WT^ were randomly selected for IHC with anti-Mps1 and anti-p-ERK antibodies. The positive expression of p-ERK protein was brown and localized in the nucleus ([Fig. 3](#f3-ol-0-0-9924){ref-type="fig"}). And the positive rate of p-ERK expression was 93.3% in colorectal cancer tissue with BRAF^V600E^, while the positive rate of p-ERK expression was 6.7% in paired normal tissues, which the difference was statistically significant in BRAF^V600E^ mutation cases ([Fig. 4A](#f4-ol-0-0-9924){ref-type="fig"}, χ^2^ test, P\<0.05). However, In BRAF^WT^ cases, there was no significant difference in the expression of p-ERK between colorectal cancer and paired normal tissues ([Fig. 4A](#f4-ol-0-0-9924){ref-type="fig"}, χ^2^ test, P\>0.05).

Further evaluations were made concerning the expression of Mps1 in colorectal cancer. the positive expression of Mps1 protein was brown and localized in the cytoplasm ([Fig. 3](#f3-ol-0-0-9924){ref-type="fig"}). The positive expression of Mps1 in CRC with BRAF^V600E^ was significantly higher compared with that in paired normal tissues ([Fig. 4B](#f4-ol-0-0-9924){ref-type="fig"}, χ^2^ test, P\<0.05). While there was no significant difference in the expression of Mps1 between colorectal cancer and paired normal tissues in BRAF^WT^ cases. ([Fig. 4B](#f4-ol-0-0-9924){ref-type="fig"}, χ^2^ test, P\>0.05).

### Association between p-ERK or Mps1 expression and clinical parameters

Subsequently, the association of expression of p-ERK and Mps1 with clinical pathological features was analyzed ([Table III](#tIII-ol-0-0-9924){ref-type="table"}). p-ERK expression was associated with LN metastasis, pathology type and degree of differentiation (χ^2^ test, P\<0.05; [Table III](#tIII-ol-0-0-9924){ref-type="table"}). The expression of p-ERK was significantly higher in poorly differentiated adenocarcinoma and mucinous adenocarcinoma compared with that in highly differentiated adenocarcinoma and non-mucinous adenocarcinoma, as well as in the group with LN metastasis compared with without LN metastasis. (χ^2^ test, P\<0.05; [Table III](#tIII-ol-0-0-9924){ref-type="table"}); however, p-ERK expression was not associated with age, sex, smoking status, drinking status, location or T stage in CRC (χ^2^ test, P\>0.05; [Table III](#tIII-ol-0-0-9924){ref-type="table"}).

Positive Mps1 expression was significantly greater in poorly differentiated carcinoma compared with in well-differentiated adenocarcinoma in CRC (χ^2^ test, P\<0.05, [Table III](#tIII-ol-0-0-9924){ref-type="table"}). There were no significant associations between positive expression of Mps1 and age, sex, smoking status, drinking status, location, pathological type, LN metastasis or T stage in CRC (χ^2^ test, P\>0.05; [Table III](#tIII-ol-0-0-9924){ref-type="table"}).

In addition, the expression of p-ERK and Mps1 between the BRAF^V600E^ and BRAF^WT^ groups were then compared, and the expression of p-ERK and Mps1 in the BRAF^V600E^ group was higher compared with those in the BRAF^WT^ group (Fisher\'s exact test, P\<0.05). Expression of p-ERK was correlated positively with the Mps1 expression, with a contingency coefficient of 0.679 (P=0.002; [Table IV](#tIV-ol-0-0-9924){ref-type="table"}). In the sensitivity analysis, it was also identified that p-ERK expression was positively correlated with the expression of Mps1 (Spearman\'s rank correlation analysis correlation coefficient 0.623; P\<0.001; [Fig. 4C](#f4-ol-0-0-9924){ref-type="fig"}).

Discussion
==========

The results of the present study demonstrated that the incidence of BRAF^V600E^ was 5.2% in CRC, which was consistent with previously published rates, between 5 and 15% ([@b19-ol-0-0-9924]--[@b24-ol-0-0-9924]). The difference mentioned above may be due to the complicated genetic background of different ethnicities. In the study by Yoon *et al* ([@b25-ol-0-0-9924]), BRAF mutation frequency in CRC from Caucasians (13.9%) was twice that of tumors from Asians (5.6%) or individuals of African (6.4%) descent.

Malignant tumors with the BRAF^V600E^ mutation have been demonstrated to be associated with mortality in patients with colorectal cancer ([@b26-ol-0-0-9924]). Numerous studies have demonstrated that the malignant tumor with BRAF^V600E^ is insensitive to the traditional treatments and patients have a poor prognosis ([@b27-ol-0-0-9924]--[@b29-ol-0-0-9924]). With the success of BRAF inhibitors in malignant melanoma, there is concern about the efficacy of BRAF inhibitors in other tumors with BRAF^V600E^ mutations ([@b9-ol-0-0-9924],[@b30-ol-0-0-9924]). However, BRAF inhibitors exhibited severe adverse effects in the treatment of patients with CRC harboring the BRAFV600E mutation ([@b31-ol-0-0-9924]). A previous clinical study compared the expression of p-ERK between pre- and post-treatment with BRAF inhibitors, but the results showed that the downregulation of p-ERK only occurred in 47% of patients with CRC harboring the BRAF^V600E^ mutation ([@b32-ol-0-0-9924]). This indicates that the inhibition of the MAPK signaling pathway by this BRAF inhibitor is insufficient, which may be a principal reason for the low response rate of BRAF inhibitors. Thus, identifying novel strategies for the full and sustained inhibition of the MAPK pathway in patients with CRC with the BRAF mutant is of marked clinical importance.

Mps1, a member of the spindle-monitoring complex, is involved in centrosome duplication and spindle checkpoint ([@b33-ol-0-0-9924]) and cell cycle regulation, and has maximum kinase activity in the M phase of the cell cycle ([@b34-ol-0-0-9924]). Typically, Mps1 is an unstable protein, which is degraded by the ubiquitin-proteasome pathway when centrosome duplication is completed, and cells enter anaphase ([@b35-ol-0-0-9924]). It has been reported that either too high or too low Mps1 kinase activity results in aberrations in centrosome duplication ([@b36-ol-0-0-9924]), lead to aneuploidy formation and result in malignant tumor formation ([@b37-ol-0-0-9924]). Currently, Mps1 has been reported in the breast, colon and other malignant tumors with high expression, and may facilitate tumor cell evasion from apoptosis, culminating in carcinogenesis ([@b38-ol-0-0-9924]--[@b40-ol-0-0-9924]). Our previous study identified that Mps1 is a downstream target of BRAF^V600E^ ([@b12-ol-0-0-9924]). Persistent phosphorylation of Mps1 through BRAF^V600E^ signaling is a key event in disrupting the control of centrosome duplication and chromosome stability that may contribute to tumorigenesis ([@b13-ol-0-0-9924]). Thus, Mps1 may serve as a novel therapeutic target for patients with CRC harboring the BRAF^V600E^ mutation.

The effect of Mps1 kinase inhibitors have been investigated in a variety of malignant tumors, with promising results ([@b41-ol-0-0-9924],[@b42-ol-0-0-9924]). The present study initially identified that Mps1 was significantly associated with BRAF^V600E^/p-ERK in CRC. It was indicated that Mps1, the downstream target of the BRAF^V600E^/MAPK/ERK kinase/ERK signaling pathway, may serve a significant function in the development of CRC. The use of a BRAF inhibitor combined with an Mps1 inhibitor may provide a novel therapeutic approach for treating patients with CRC harboring the BRAF^V600E^ mutation, who were previously resistant or insensitive to the BRAF inhibitor.

However, there were some limitations to the present study. For example, the data pertaining to the 5-year survival rate are still being collected, and the sample size of BRAF^V600E^ is not large enough, which leads to the lack of representativeness. However, even if the sample size of BRAF^V600E^ is small, the data still conform to the normal distribution, ensuring the accuracy and integrity of the results. We will analyze the 5-year survival data in further study. More samples of BRAF^V600E^ will be selected in statistical analysis in further research.

In conclusion, the present study demonstrated that Mps1 was significantly associated with BRAF^V600E^/p-ERK and may serve a crucial function in the development of CRC. Targeting the oncogenic BRAF^V600E^ and Mps1, particularly when used in combination, could potentially provide therapeutic opportunities for the treatment of cancer.
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![Sanger sequencing peak map of BRAF. (A) Sanger sequencing peak map of BRAF^V600E^. The BRAF^V600E^ mutation shows additional peaks compared with the wild-type, which is indicated by the grey box. (B) Sanger Sequencing peak map of BRAF^WT^. The site at position 1796 was not mutated. (C) Kaplan-Meier survival analysis indicated that the survival rate was significantly lower in patients with BRAF^V600E^ mutation compared with those with BRAF. BRAF, B-Raf proto-oncogene serine/threonine kinase; WT, wild-type.](ol-17-03-2809-g00){#f1-ol-0-0-9924}

![Multivariate and univariate analyses of survival prognosis in CRC. (A) Multivariate analyses of survival prognosis in CRC (B) Univariate analysis of survival prognosis in CRC. BRAF, WT vs. V600E; pathological stage, I--II vs. III--IV; M stage, M0 vs. M1; N stage, N0 vs. N1; T stage, T1-2 vs. T3-4; differentiation, poor vs. medium + well; histological, mucous adenocarcinoma vs. others; family history, yes vs. no; drinking, yes vs. no; smoking, yes vs. no; age at diagnosis, ≥60 years vs. \<60 years; sex, male vs. female. CRC, colorectal cancer; BRAF, B-Raf proto-oncogene serine/threonine kinase; WT, wild-type; HR, hazard ratio; T, tumor; N, node; M, metastasis. The bracketed values represent 95% confidence intervals.](ol-17-03-2809-g01){#f2-ol-0-0-9924}

![Representative immunohistochemistry images revealed p-ERK or Mps1 staining in colorectal cancer and corresponding normal tissues with BRAF^WT^ or BRAF^V600E^ mutations, at ×100 magnifcation. In the BRAF^V600E^ mutation of colorectal cancer, the positive expression of p-ERK and Mps1 protein were brown and localized in the nucleus and the cytoplasm respectively, while in the normal tissues with BRAF^V600E^ mutation, the expression of pERK and Mps1 was negtive. In the colorectal cancer with BRAF^WT^, there was no significant difference in the expression of p-ERK or Mps1 between colorectal cancer and paired normal tissues. p-ERK, phospho-extracellular-signal-regulated kinase; Mps1, monopolar spindle protein kinase 1. (×100 magnification).](ol-17-03-2809-g02){#f3-ol-0-0-9924}

![Mps1 is significantly associated with BRAF^V600E^/p-ERK. (A) The expression of p-ERK between BRAF^V600E^ and BRAF^WT^. (B) The expression of Mps1 between BRAF^V600E^ and BRAF^WT^. (C) A sensitivity analysis was conducted using Spearman\'s rank correlation analysis in order to evaluate the correlation between p-ERK and Mps1. The results demonstrated that p-ERK expression was positively correlated with Mps1 expression (contingency coefficient, 0.623; P\<0.001). BRAF, B-Raf proto-oncogene serine/threonine kinase; Mps1, monopolar spindle protein kinase 1; p-ERK, phospho-extracellular-signal-regulated kinase; WT, wild-type \*P\<0.05. The p-ERK and Mps1 positive expression levels between colorectal cancer and paired normal tissues in BRAF^V600E^ group is statistically significant (P\<0.05); NS. The p-ERK and Mps1 positive expression levels between colorectal cancer and paired normal tissues in BRAF^WT^ group is not statistically significant (P\>0.05).](ol-17-03-2809-g03){#f4-ol-0-0-9924}

###### 

Clinicopathological information of the 288 patients with colorectal cancer in the present study.

  Clinicopathological feature                                           n
  --------------------------------------------------------------------- -----
  Sex                                                                   
    Male                                                                156
    Female                                                              132
  Age, years                                                            
    \>60                                                                195
    ≤60                                                                 93
  Smoking status                                                        
    Yes                                                                 47
    No                                                                  241
  Drinking status                                                       
    Yes                                                                 259
    No                                                                  29
  Differentiation                                                       
    Well                                                                51
    Medium and poor                                                     237
  Pathological pattern                                                  
    Mucinous carcinoma                                                  24
    Other                                                               264
  T^[a](#tfn1-ol-0-0-9924){ref-type="table-fn"}^ (infiltration depth)   
    \>T3                                                                79
    ≤T3                                                                 209
  Lymph node metastasis                                                 
    Positive                                                            110
    Negative                                                            178
  Clinical stage (15)                                                   
    I--II                                                               169
    III--IV                                                             119
  Location                                                              
    Rectum                                                              125
    Colon                                                               163

\>T3 includes T4a (tumor penetrates to the surface of the visceral peritoneum) and T4b (tumor directly invades or is adherent to other organs or structures). ≤T3 includes T1 (tumor invades submucosa), T2 (tumor invades muscularis propria) and T3 (tumor invades through the muscularis propria into the pericolorectal tissues) according to NCCN Guidelines version 2.2015 Staging Colon Cancer (15). LN, lymph node.

###### 

Association between BRAF^V600E^ mutation and clinicopathological parameters in colorectal cancer.

                                                                        BRAF^V600E^ mutation         
  --------------------------------------------------------------------- ---------------------- ----- ---------
  Sex                                                                                                0.739
    Male                                                                7                      149   
    Female                                                              8                      124   
  Age, years                                                                                         0.043
    \>60                                                                14                     181   
    ≤60                                                                 1                      92    
  Smoking status                                                                                     0.142
    Yes                                                                 0                      47    
    No                                                                  15                     226   
  Drinking status                                                                                    0.378
    Yes                                                                 0                      29    
    No                                                                  15                     244   
  Differentiation                                                                                    0.082
    Well                                                                0                      51    
    Medium and poor                                                     15                     222   
  Pathological pattern                                                                               0.001
    Mucinous carcinoma                                                  6                      18    
    Others                                                              9                      255   
  T^[a](#tfn2-ol-0-0-9924){ref-type="table-fn"}^ (infiltration depth)                                \<0.001
    \>T3                                                                15                     64    
    ≤T3                                                                 0                      209   
  Lymph node metastasis                                                                              0.882
    Positive                                                            6                      104   
    Negative                                                            9                      169   
  Clinical stage (15)                                                                                0.871
    I--II                                                               8                      161   
    III--IV                                                             7                      112   
  Location                                                                                           0.107
    Rectum                                                              3                      122   
    Colon                                                               12                     151   

\>T3 includes T4a (tumor penetrates to the surface of the visceral peritoneum) and T4b (tumor directly invades or is adherent to other organs or structures). ≤T3 includes T1 (tumor invades submucosa), T2 (tumor invades muscularis propria) and T3 (tumor invades through the muscularis propria into the pericolorectal tissues) according to NCCN Guidelines version 2.2015 Staging Colon Cancer (15). BRAF, B-Raf proto-oncogene serine/threonine kinase.

###### 

Association between p-ERK/Mps1 and clinicopathological parameters in colorectal cancer.

                                                                        p-ERK in tumor   Mps1 in tumor                     
  --------------------------------------------------------------------- ---------------- --------------- ------- ---- ---- -------
  Sex                                                                                                                      
    Male                                                                10               9                       9    10   
    Female                                                              7                4               0.558   9    2    0.121
  Age, years                                                                                                               
    \>60                                                                15               11                      17   9    
    ≤60                                                                 2                2               0.773   1    3    0.274
  Smoking status                                                                                                           
    Yes                                                                 1                1                       0    2    
    No                                                                  16               12              0.844   18   10   0.152
  Drinking status                                                                                                          
    Yes                                                                 1                0                       0    1    
    No                                                                  16               13              1.000   18   11   0.400
  Differentiation                                                                                                          
    Well                                                                1                6                       1    6    
    Medium and poor                                                     16               7               0.01    17   6    0.009
  Pathological pattern                                                                                                     
    Mucinous carcinoma                                                  6                0                       6    0    
    Others                                                              11               13              0.024   12   12   0.057
  T^[a](#tfn3-ol-0-0-9924){ref-type="table-fn"}^ (infiltration depth)                                                      
    \>T3                                                                4                1                       5    0    
    ≤T3                                                                 13               12              0.355   13   12   0.066
  Lymph node metastasis                                                                                                    
    Positive                                                            8                1                       6    3    
    Negative                                                            9                12              0.02    12   9    0.626
  Clinical stage (15)                                                                                                      
    I--II                                                               8                9                       10   7    
    III--IV                                                             9                4               0.225   8    5    0.88
  Location                                                                                                                 
    Rectum                                                              13               9                       14   8    
    Colon                                                               4                4               0.698   4    4    0.679

\>T3 includes T4a (tumor penetrates to the surface of the visceral peritoneum) and T4b (tumor directly invades or is adherent to other organs or structures). ≤T3 includes T1 (tumor invades submucosa), T2 (tumor invades muscularis propria) and T3 (tumor invades through the muscularis propria into the pericolorectal tissues) according to NCCN Guidelines version 2.2015 Staging Colon Cancer (15). p-ERK, phospho-extracellular-signal-regulated kinase; Mps1, monopolar spindle protein kinase 1.

###### 

Association between the p-ERK or Mps1 expression and BRAF mutation in colorectal cancer.

                p-ERK        Mps1                                        
  ------------- ------------ ---------- --------- ----------- ---------- -------
  BRAF^V600E^   14 (93.3%)   1 (6.7%)             15 (100%)   0 (0%)     
  BRAF^WT^      3 (20%)      12 (80%)   \<0.001   3 (20%)     12 (80%)   0.002

CRC, colorectal cancer; BRAF, B-Raf proto-oncogene serine/threonine kinase; p-ERK, phospho-extracellular-signal-regulated kinase; Mps1, monopolar spindle protein kinase 1; WT, wild-type.
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